GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab AS (NAS:GMAB) » Definitions » Enterprise Value

GMAB (Genmab AS) Enterprise Value : $10,918 Mil (As of Dec. 12, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Genmab AS Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Genmab AS's Enterprise Value is $10,918 Mil. Genmab AS's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 was $963 Mil. Therefore, Genmab AS's EV-to-EBIT ratio for today is 11.33.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Genmab AS's Enterprise Value is $10,918 Mil. Genmab AS's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 was $989 Mil. Therefore, Genmab AS's EV-to-EBITDA ratio for today is 11.04.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Genmab AS's Enterprise Value is $10,918 Mil. Genmab AS's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 was $2,904 Mil. Therefore, Genmab AS's EV-to-Revenue ratio for today is 3.76.


Genmab AS Enterprise Value Historical Data

The historical data trend for Genmab AS's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab AS Enterprise Value Chart

Genmab AS Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12,889.57 24,020.07 23,124.36 24,610.75 16,797.42

Genmab AS Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19,211.16 16,797.42 15,318.40 13,826.85 13,053.68

Competitive Comparison of Genmab AS's Enterprise Value

For the Biotechnology subindustry, Genmab AS's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genmab AS's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab AS's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Genmab AS's Enterprise Value falls into.



Genmab AS Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Genmab AS's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

Genmab AS's Enterprise Value for the quarter that ended in Sep. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genmab AS  (NAS:GMAB) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Genmab AS's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=10917.964/963.355
=11.33

Genmab AS's current Enterprise Value is $10,918 Mil.
Genmab AS's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $963 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Genmab AS's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=10917.964/988.513
=11.04

Genmab AS's current Enterprise Value is $10,918 Mil.
Genmab AS's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $989 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Genmab AS's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=10917.964/2903.998
=3.76

Genmab AS's current Enterprise Value is $10,918 Mil.
Genmab AS's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $2,904 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genmab AS Enterprise Value Related Terms

Thank you for viewing the detailed overview of Genmab AS's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Genmab AS Business Description

Address
Carl Jacobsens Vej 30, Valby, DNK, 2500
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.